Optimizing CGM and CKM Data Across Populations, Interpretation, Integration, and Clinical Decision-Making (Pharmacy Technician Credit)

This activity was originally presented at the 2026 Diabetes Day of Education.

Program Description

While continuous glucose monitoring (CGM) has shifted the management of diabetes, the true clinical impact of CGM technology relies on a pharmacist’s ability to translate data into actionable therapeutic adjustments and the pharmacy technician’s ability to support people living with diabetes to ensure optimal use. In this collaborative panel discussion, experts will move beyond basic device features to focus on the high-level interpretation of ambulatory glucose profile reports with an illustrative discussion on how to efficiently identify patterns indicating concerns such as hyperglycemia or potentially dangerous nocturnal hypoglycemia episodes. Panelists will emphasize a holistic approach to patient care, exploring how pharmacists and pharmacy technicians can provide support and ensure long-term CGM persistence through streamlined data-sharing workflows and optimized alert settings. Pharmacists and pharmacy technicians will gain a deeper understanding of the interoperability between CGMs, automated insulin delivery systems, and other tools, ensuring they can identify ideal candidates for these advanced integrations. By examining best practices for motivational interviewing and clinical follow-up, this panel will provide attendees with practical insights and tips for integrating digital health tools into community practice settings to drive measurable improvements in glycemic outcomes for people living with diabetes.

Target audience: Community pharmacists

Type of activity: Application

Release date: May 22, 2026

Expiration date: May 22, 2027

Learner level: Intermediate, Foundational

Time to complete activity: 1.5 hours

Fee: Free

Educational Objectives

At the completion of this activity, pharmacy technicians will be able to:

• Identify candidates for continuous glucose monitoring (CGM), automated insulin delivery systems, and emerging technologies (including continuous ketone monitoring)
• Determine the use of CGM data and ambulatory glucose profile reports for treatment adjustments and optimizing results
• Explore team-based strategies to support people living with diabetes across varied care settings
• Examine solutions to overcome barriers to technology utilization from initiation to long-term use

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity numbers 0290-0000-26-151-H01-P and 0290-0000-26-151-H01-T. The activity is available for CE credit through May 22, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: MiniMed, Tandem

Speakers Bureau: Abbott, CeQur, Dexcom, Insulet, Lilly, Novo Nordisk, Sanofi, Sequel Pharma

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Abbott Diabetes, Amgen, CeQur, Lilly, Novo Nordisk, Xeris

Natalie Bellini, DNP, FNP-BC, BC-ADM, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Dexcom, Medtronic, Sanofi

Speakers Bureau: Abbott, Dexcom, Sanofi, Sequel

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Association of Diabetes Care and Education Specialists

Speakers Bureau: Abbott Diabetes Care, Insulet, Sanofi, Xeris

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms